A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats.

This article presents a comparative study on the benefits of different treatments for rats with streptozotocin-induced diabetes. The study found that a combination therapy of insulin, rosiglitazone, and gemfibrozil was more effective in controlling blood sugar and lipid levels compared to individual treatments. The combination therapy also had a positive effect on lipid levels, reducing cholesterol and triglycerides while increasing HDL. The study suggests that this combination therapy may help prevent cardiovascular events associated with diabetes. [Extracted from the article]